ACADIA Pharmaceuticals Inc. (ACAD): Price and Financial Metrics

ACADIA Pharmaceuticals Inc. (ACAD)

Today's Latest Price: $49.68 USD

1.01 (-1.99%)

Updated May 29 4:00pm

Add ACAD to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ACAD Stock Summary

  • For ACAD, its debt to operating expenses ratio is greater than that reported by merely 5.78% of US equities we're observing.
  • With a price/sales ratio of 21.56, Acadia Pharmaceuticals Inc has a higher such ratio than 93.84% of stocks in our set.
  • Revenue growth over the past 12 months for Acadia Pharmaceuticals Inc comes in at 53.93%, a number that bests 90.36% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Acadia Pharmaceuticals Inc, a group of peers worth examining would be MRAM, JG, ESTC, NSTG, and PSNL.
  • Visit ACAD's SEC page to see the company's official filings. To visit the company's web site, go to
ACAD Daily Price Range
ACAD 52-Week Price Range

ACAD Stock Price Chart More Charts

ACAD Price/Volume Stats

Current price $49.68 52-week high $53.70
Prev. close $50.69 52-week low $21.56
Day low $48.00 Volume 1,214,039
Day high $51.32 Avg. volume 1,353,568
50-day MA $46.08 Dividend yield N/A
200-day MA $42.07 Market Cap 7.74B

ACADIA Pharmaceuticals Inc. (ACAD) Company Bio

Acadia Healthcare Company is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders. The company was founded in 1993 and is based in San Diego, California.

ACAD Latest News Stream

Event/TimeNews Detail
Loading, please wait...

ACAD Latest Social Stream

Loading social stream, please wait...

View Full ACAD Social Stream

Latest ACAD News From Around the Web

Below are the latest news stories about Acadia Pharmaceuticals Inc that investors may wish to consider to help them evaluate ACAD as an investment opportunity.

ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today announced that Mark Schneyer has been appointed to the newly created position of Senior Vice President, Business Development and Chief Business Officer. Mr. Schneyer will be responsible for sourcing and executing business development opportunities and serve as a member of the company’s Executive Management Committee. He will report to Steve Davis, Chief Executive Officer.

Yahoo | May 28, 2020

ACADIA to Merge Two Phase III Studies on Nuplazid for MDD

ACADIA (ACAD) to club two late-stage studies on Nuplazid into a single evaluation program for the adjunctive treatment of MDD. Top-line results from the same are expected in Q3.

Yahoo | May 27, 2020

ACADIA Pharmaceuticals to Combine CLARITY-2 and CLARITY-3 Phase 3 Studies Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that following positive feedback from the U.S. Food and Drug Administration the company plans to combine its CLARITY-2 and CLARITY-3 Phase 3 studies evaluating pimavanserin for the adjunctive treatment of major depressive disorder (MDD) into one study with a pre-specified statistical analysis plan. As a result, no new patients will be enrolled in the two identically designed Phase 3 studies, each of which wil

Business Wire | May 26, 2020

Edited Transcript of ACAD earnings conference call or presentation 7-May-20 8:30pm GMT

Q1 2020 ACADIA Pharmaceuticals Inc Earnings Call

Yahoo | May 22, 2020

ACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020 American Society of Clinical Psychopharmacology Virtual Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that multiple scientific presentations and abstracts evaluating pimavanserin in clinical studies for the treatment of various central nervous system (CNS) disorders will be highlighted at the 2020 American Society of Clinical Psychopharmacology (ASCP) Virtual Annual Meeting on May 29-30, 2020. “Our research presentations at ASCP underscore the potential clinical utility of pimavanserin in serious CNS disorder

Business Wire | May 21, 2020

Read More 'ACAD' Stories Here

ACAD Price Returns

1-mo -2.13%
3-mo 16.24%
6-mo 9.69%
1-year 99.52%
3-year 93.68%
5-year 20.58%
YTD 16.13%
2019 164.56%
2018 -46.30%
2017 4.40%
2016 -19.10%
2015 12.28%

Continue Researching ACAD

Here are a few links from around the web to help you further your research on Acadia Pharmaceuticals Inc's stock as an investment opportunity:

Acadia Pharmaceuticals Inc (ACAD) Stock Price | Nasdaq
Acadia Pharmaceuticals Inc (ACAD) Stock Quote, History and News - Yahoo Finance
Acadia Pharmaceuticals Inc (ACAD) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8545 seconds.